Cardinal Health, Inc. vs The Procter & Gamble Company: Strategic Comparison

This in-depth comparison examines Cardinal Health, Inc. and The Procter & Gamble Company across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Cardinal Health, Inc. on its own, evaluating The Procter & Gamble Company, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Cardinal Health, Inc. and The Procter & Gamble Company is widest.

On the headline numbers, Cardinal Health, Inc. reports annual revenue of $254.2B against $87.0B for The Procter & Gamble Company, while their respective market capitalizations stand at $56.0B and $340.0B. Both Cardinal Health, Inc. and The Procter & Gamble Company are headquartered in United States, so they compete in a shared home market and regulatory environment.

Cardinal Health, Inc.: Cardinal Health, based in Ohio, is one of the three large US pharmaceutical distributors, along with McKesson and Cencora. It does not invent drugs or treat patients. It runs the regulated supply chain that moves medicines and medical devices from manufacturers to pharmacies and hospitals, so a prescription collected at a local pharmacy has often passed through its network.

The Procter & Gamble Company: Procter & Gamble is one of the world's largest consumer packaged goods companies, selling everyday brands including Tide, Pampers, Gillette, Crest, Oral-B, Charmin, Bounty, Dawn and Head & Shoulders. Founded in Cincinnati in 1837 and still headquartered there, it reported $87.0 billion in fiscal 2026 net sales, employs roughly 109,000 people and is a component of the Dow Jones Industrial Average. Its stock trades on the NYSE under PG, with a market value of roughly $340 billion in September 2026.

Cardinal Health, Inc. and The Procter & Gamble Company pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Cardinal Health, Inc. and The Procter & Gamble Company.

Cardinal Health, Inc. business model: The business model is large, high-volume logistics divided into two segments: Pharmaceutical and Medical. In the Pharma segment, they buy billions of dollars of drugs from manufacturers (like Pfizer) and distribute them daily to tens of thousands of pharmacies and hospitals, taking a tiny markup. In the Medical segment, they actually manufacture and distribute low-cost, high-volume medical supplies (like surgical gloves, gowns, and syringes), acting as the large central supply closet for the entire American hospital system.

The Procter & Gamble Company business model: P&G makes money by designing, manufacturing and marketing branded household and personal-care products that consumers buy every week, then selling them through retailers, club stores, pharmacies, distributors and e-commerce platforms. Revenue comes from five reportable segments: Fabric & Home Care (Tide, Ariel, Dawn, Downy, Febreze), the largest; Baby, Feminine & Family Care (Pampers, Always, Bounty, Charmin); Beauty (Olay, Pantene, Head & Shoulders, SK-II); Health Care (Crest, Oral-B, Vicks); and Grooming (Gillette, Venus, Braun). Walmart is its largest customer. Profit depends on premium pricing backed by product performance, purchasing and manufacturing scale, and heavy, data-driven advertising.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Cardinal Health, Inc. stack up against those of The Procter & Gamble Company.

Cardinal Health, Inc. competitive advantage: Cardinal Health's advantage is physical scale and regulatory standing. Moving regulated, temperature-sensitive drugs and biologics across the country overnight takes a network of specialized distribution centers and security procedures that cost billions of dollars and take decades to build. The barrier to entry is high, so drug distribution is concentrated among a few large companies.

The Procter & Gamble Company competitive advantage: P&G's edge is the combination of category leadership and scale. It concentrates on about ten daily-use categories where performance differences are visible to consumers (cleaning, absorbency, shaving, oral care), funds roughly $2 billion a year of R&D to keep those gaps, and uses its size to buy materials, media and logistics more cheaply than smaller rivals. Its brands are traffic drivers for retailers, which gives P&G strong shelf positioning and joint-planning relationships with chains such as Walmart, Costco and Amazon.

Future prospects matter as much as current results. The growth strategies below explain how Cardinal Health, Inc. and The Procter & Gamble Company each plan to expand from here.

Cardinal Health, Inc. growth strategy: Cardinal Health's growth plan rests on three levers. First, specialty pharmaceuticals and physician practice platforms: it bought a 71% stake in GI Alliance for about $2.8 billion (announced November 2024) and funded The Specialty Alliance's roughly $1.9 billion acquisition of urology MSO Solaris Health (completed November 2025). Second, the Other segment: Nuclear and Precision Health Solutions (radiopharmaceuticals and theranostics), at-Home Solutions (expanded with ADSG in 2025, Strive Medical, and the announced AdaptHealth diabetes business), and OptiFreight Logistics, which together grew revenue 26% to $6.8 billion in fiscal 2026. Third, improving GMPD profitability through its Cardinal Health brand products and cost actions.

The Procter & Gamble Company growth strategy: P&G's integrated growth strategy has five parts: a portfolio focused on about ten daily-use categories, superiority across product, packaging, communication, retail execution and value, productivity savings to fund reinvestment, 'constructive disruption' of its own practices, and an agile, accountable organization. In June 2025 the company announced a two-year restructuring that includes exiting some brands and product forms in certain markets and cutting up to 7,000 non-manufacturing roles, about 15% of that workforce. Under Jejurikar the emphasis has shifted toward consumer-first innovation, digital media and faster decision-making.

A closer look at the financial trajectory of Cardinal Health, Inc. and The Procter & Gamble Company rounds out the comparison.

Cardinal Health, Inc.: Cardinal Health combines very large revenue with thin margins. Fiscal 2026 revenue was $254.2 billion, up 14% from $222.6 billion in fiscal 2025, driven by brand and specialty drug volume from existing customers. GAAP operating earnings were $2.6 billion, GAAP diluted EPS was $7.23, and net earnings attributable to Cardinal Health were about $1.7 billion. Non-GAAP diluted EPS rose 37% to $11.26 ($10.95 excluding the IEEPA tariff refund). Operating cash flow was $5.2 billion and adjusted free cash flow was $5.0 billion. The company repurchased $1.4 billion of stock in fiscal 2026 and the board added $5.0 billion to the buyback authorization in August 2026. Fourth-quarter fiscal 2026 revenue was $63.7 billion, up 6%.

The Procter & Gamble Company: P&G's finances are defined by steady sales, high margins and large cash returns rather than fast growth. Net sales rose from $65.1 billion in fiscal 2017 to $87.0 billion in fiscal 2026. In fiscal 2026 diluted EPS was $6.62 (up 2%) and core EPS was $6.89 (up 1%), with core gross and operating margins slipping 40 and 70 basis points as costs rose. The company returned more than $15 billion to shareholders, about $10.2 billion in dividends and $5 billion in buybacks, and has raised its dividend for 70 consecutive years. For fiscal 2027 it guided to 1%-3% organic sales growth and core EPS of $6.89-$7.11.